Elizabeth D. Barnett

Elizabeth D. Barnett

Auto-generated profile, based on publicly available information

Elizabeth D. Barnett

Section of Pediatric Infectious Diseases, Boston University Chobanian and Avedisian School of Medicine, 72 East Concord Street, Boston, MA, 02118, USA

Research Focus & Metrics

Academic Career Length

58Years (1969-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2013 in Annals of Internal Medicine
Verified
Journal Article
Closed access
KLKarin Leder
Karin Leder
Joseph TorresiJoseph Torresi
Joseph Torresi
MLMichael D. Libman
Michael D. Libman
JCJakob P. Cramer
Jakob P. Cramer
Francesco CastelliFrancesco Castelli
Francesco Castelli
FNfor the GeoSentinel Surveillance Network
for the GeoSentinel Surveillance Network
International travel is rapidly increasing, as are travelers presenting with illness after they return home. Researchers used a large surveillance database to examine the frequency and patterns of ... Chinese translation Background: International travel continues to increase, particularly to Asia and Africa. Clinicians are increasingly likely to be consulted for advice before travel or by ill re...

1 November 2008 in Vaccine
Verified
Journal Article
Open access
NLNicole P. Lindsey
Nicole P. Lindsey
BSBetsy A. Schroeder
Betsy A. Schroeder
EMElaine R. Miller
Elaine R. Miller
MBM. Miles Braun
M. Miles Braun
AHAlison F. Hinckley
Alison F. Hinckley
EHEdward B. Hayes
Edward B. Hayes
Yellow fever (YF) vaccine has been used for prevention of YF since 1937 with over 500 million doses administered. However, rare reports of severe adverse events following vaccination have raised concerns about the vaccine's safety. We reviewed reports of adverse events following YF vaccination reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) from 2000 to 2006. We used estimates of age and sex distribution of administered doses obtained from a 2006 survey of authorized vaccine providers to calculate age- and sex-specific reporting rates of all serious adverse events (SAE), anaphylaxis, YF vaccine-associated neurotropic disease, and YF vaccine-associated viscerotropic disease. Reporting rates of SAEs were substantially higher in males and in persons aged > or =60 years. These findings reinforce the generally acceptable safety profile of YF vaccine, but highlight the importance of physician and traveler education regarding the risks and benefits of YF vaccination, particularly for travelers > or =60 years of age. Vaccination should be limited to persons traveling to areas where the risk of YF is expected to exceed the risk of serious adverse events after vaccination, or if not medically contraindicated, where national regulations require proof of vaccination to prevent introduction of YF.

15 March 2007 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
EBElizabeth D. Barnett
Elizabeth D. Barnett
Yellow fever continues to occur in regions of Africa and South America, despite the availability of effective vaccines. Recently, some cases of sever

1 May 2010 in Pediatrics
Verified
Journal Article
Closed access
PDF file
SHStefan Hagmann
Stefan Hagmann
RNRichard Neugebauer
Richard Neugebauer
ESEli Schwartz
Eli Schwartz
CPCecilia Perret
Cecilia Perret
Francesco CastelliFrancesco Castelli
Francesco Castelli
FNfor the GeoSentinel Surveillance Network
for the GeoSentinel Surveillance Network
OBJECTIVE: By using a large, multicenter database, we investigated the characteristics and morbidities of 1591 children returning from 218 global destinations and presenting for care in 19 countries. METHODS: Data reported to the GeoSentinel Surveillance Network between January 1997 and November 2007 were analyzed, to assess demographic features, travel characteristics, and clinical diagnoses of ill pediatric travelers. Data were compared between children and adults and among 3 pediatric age groups (0–5 years, 6–11 years, and 12–17 years). RESULTS: Children were predominantly tourist travelers returning from Asia, sub-Saharan Africa, or Latin America. Compared with adults, children disproportionately presented within 7 days after return, required hospitalization, lacked pretravel health advice, and had traveled for the purpose of visiting friends and relatives. Diarrhea (28%), dermatologic conditions (25%), systemic febrile illnesses (23%), and respiratory disorders (11%) accounted for the majority of diagnoses reported for children. No fatalities were reported. Diarrhea occurred disproportionately among children after exposure to the Middle East/North Africa, dermatologic conditions after exposure to Latin America, systemic febrile illnesses after exposure to sub-Saharan Africa or Asia, and respiratory disorders after exposure to Europe or North America. The proportionate morbidity rates of travel-associated diseases differed among the pediatric age groups and between children and adults. CONCLUSIONS: The health care utilization patterns before and after travel and the profiles of travel-associated health problems differed between children and adults. Health professionals providing pretravel advice need to consider destination- and age-specific susceptibility to travel-related morbidities and develop prevention strategies accordingly.

1 October 2020 in Placenta
Verified
Journal Article
Closed access
ETElizabeth Taglauer
Elizabeth Taglauer
YBYoel Benarroch
Yoel Benarroch
KRKevin Rop
Kevin Rop
EBElizabeth Barnett
Elizabeth Barnett
VSVishakha Sabharwal
Vishakha Sabharwal
EWElisha M Wachman
Elisha M Wachman

1 October 2010 in Vaccine
Verified
Journal Article
Closed access
ABAndrea K Boggild
Andrea K Boggild
Francesco CastelliFrancesco Castelli
Francesco Castelli
PGPhilippe Gautret
Philippe Gautret
Joseph TorresiJoseph Torresi
Joseph Torresi
FSFrank von Sonnenburg
Frank von Sonnenburg
MWMary E. Wilson
Mary E. Wilson